PL EN


Preferences help
enabled [disable] Abstract
Number of results
2018 | 28 | 110 | 4-10
Article title

THE USE OF SULFONAMIDES IN THE PHARMACOTHERAPY OF INFECTIOUS DISEASES OF HUMANS AND ANIMALS AND THE ASSOCIATED ENVIRONMENTAL RISK

Content
Title variants
PL
ZASTOSOWANIE SULFONAMIDÓW W FARMAKOTERAPII CHORÓB ZAKAŹNYCH LUDZI I ZWIERZĄT ORAZ ZWIĄZANE Z TYM ZAGROŻENIA DLA ŚRODOWISKA
Languages of publication
PL EO
Abstracts
EN
Sulfonamides are one of the oldest antibacterial drugs that remain still in use in humans and animals treatment. These compounds block the biosynthesis of folate in bacterial cells, thus inhibiting growth of bacteria. In order to potentiate the pharmacological activity, sulfonamides are often combined with trimethoprim. The role of those bacteriostatic agents has decreased over the years, mainly due to increasing bacterial resistance which is an effect of the inappropriate use of sulfonamides. There are still several compounds which are administered in humans to treat not only bacterial infections, but also protozoan ones (e.g. toxoplasmosis), for instance sulfamethoxazole, sulfacetamide, sulfathiazole. More number of sulfonamides is used in veterinary. According to this fact, there is a considerable adverse effect of those compounds on the environment: sulfonamides, after having been excreted from animal organisms, are present in soil and water, including groundwater. Hence there is a strong need to find effective methods of sulfonamides degradation in order to protect the environment.
Publisher

Year
Volume
28
Issue
110
Pages
4-10
Physical description
Contributors
  • Jagiellonian University Medical College, Faculty of Pharmacy, Department of Inorganic and Analitycal Chemistry, Medyczna 9, 30-688 Kraków, adrian.podkowa@uj.edu.pl
  • Jagiellonian University Medical College, Faculty of Pharmacy, Department of Inorganic and Analitycal Chemistry, Medyczna 9, 30-688 Kraków, Jagiellonian University Medical College, Faculty of Pharmacy, Department of Pharmaceutical Botany, Medyczna 9, 30-688 Kraków
  • Jagiellonian University Medical College, Faculty of Pharmacy, Department of Inorganic and Analitycal Chemistry, Medyczna 9, 30-688 Kraków
  • Jagiellonian University Medical College, Faculty of Pharmacy, Department of Pharmaceutical Botany, Medyczna 9, 30-688 Kraków
References
  • 1. Rubin RP. A Brief History of Great Discoveries in Pharmacology: In Celebration of the Centennial Anniversary of the Founding of the American Society of Pharmacology and Experimental Therapeutics. Pharmacol Rev. 2007;59(4):289–359.
  • 2. Fermér C, Swedberg G. Adaptation to sulfonamide resistance in Neisseria meningitidis may have required compensatory changes to retain enzyme function: kinetic analysis of dihydropteroate synthases from N. meningitidis expressed in a knockout mutant of Escherichia coli. J Bacteriol. 1997;179(3):831–7.
  • 3. Livermore DM. Current Epidemiology and Growing Resistance of Gram-Negative Pathogens. Korean J Intern Med. 2012 Jun;27(2):128–42.
  • 4. Ho JM-W, Juurlink DN. Considerations when prescribing trimethoprim–sulfamethoxazole. C Can Med Assoc J. 2011;183(16):1851–8.
  • 5. Del Rosso JQ. The Use of Sodium Sulfacetamide 10%-Sulfur 5% Emollient Foam in the Treatment of Acne Vulgaris. J Clin Aesthet Dermatol. 2009;2(8):26–9. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2923965/
  • 6. Wyatt D, McGowan DN, Najarian MP. Comparison of a hydrocolloid dressing and silver sulfadiazine cream in the outpatient management of second-degree burns. J Trauma. 1990;30(7):857–65.
  • 7. Brand RA. The Use of Sulfathiazole in the Treatment of Subacute and Chronic Osteomyelitis: Frank D. Dickson MD (1882–1964), Rex L. Diveley MD, Richard Kiene MD The 4th President of the AAOS 1935 (FDD). Clin Orthop Relat Res. 2008 Jan 3;466(1):37–40.
  • 8. Feldman PA, Wolfson D, Barkin JS. Medical Management of Crohn’s Disease. Clin Colon Rectal Surg. 2007;20(4):269–81.
  • 9. Phipatanakul W, Adkinson NF. Cross-Reactivity Between Sulfonamides and Loop or Thiazide Diuretics: Is it a Theoretical or Actual Risk? Allergy Clin Immunol Int. 2000;12(1):26–8.
  • 10. Sola D, Rossi L, Schianca GPC, Maffioli P, Bigliocca M, Mella R, Corlianò F, Fra GP, Bartoli E, Derosa G. Sulfonylureas and their use in clinical practice. Arch Med Sci. 2015;11(4):840–8.
  • 11. Remko M, von der Lieth C-W. Theoretical study of gas-phase acidity, pKa, lipophilicity, and solubility of some biologically active sulfonamides. Bioorg Med Chem. 2004;12(20):5395–403.
  • 12. Rubino JT. Solubilities and solid state properties of the sodium salts of drugs. J Pharm Sci. 1989;78:485–9.
  • 13. Wood WB. Studies on the antibacterial action of the sulfonamide drugs: I. The relation of p-aminobenzoic acid to the mechanism of bacteriostasis. J Exp Med [Internet]. 1942;75(4):369–81.
  • 14. Achari A, Somers DO, Champness JN, Bryant PK, Rosemond J, Stammers DK. Crystal structure of the anti-bacterial sulfonamide drug target dihydropteroate synthase. Nat Struct Biol. 1997;4:490-7.
  • 15. Fischbach H, Welch H, King EQ, Levine J, Price CW, Randall WA. Procaine Penicillin and Sulfonamide Antagonism. J Am Pharm Assoc. 1949;38(10):544–6.
  • 16. Vicente D, Pérez-Trallero E. Tetraciclinas, sulfamidas y metronidazol. Enferm Infecc Microbiol Clin. 2010;28(2):122–30.
  • 17. Georgiev SV. Management of toxoplasmosis. Drugs. 1994;48(2):179–88.
  • 18. Hughes WT, Killmar J. Monodrug efficacies of sulfonamides in prophylaxis for Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1996;40(4):962–5.
  • 19. Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G. Rang i Dale Farmakologia. Mirowska-Guzel D, Członkowski A, Okopień B (red.). Wrocław: Elsevier Urban&Partner; 2012.
  • 20. Brunton LL, Lazo JS, Parker KL. Farmakologia Goodmana i Gilmana. Krzemiński TF, Buczko W, Czuczwar SJ (red.). Lublin; 2007.
  • 21. Masters P, O’Bryan T, Zurlo J, Miller D, Joshi N. Trimethoprim-sulfamethoxazole revisited. Arch Intern Med. 2003;163(4):402–10.
  • 22. bazalekow.mp.pl/leki/doctor_subst.html?id=1025 [15.06.2018].
  • 23. bazalekow.mp.pl/lek/27409,Argosulfan-krem [15.06.2018].
  • 24. chpl.com.pl/data_files/2013-04-19_CHPL.pdf [15.06.2018].
  • 25. Plosker GL, Croom KF. Sulfasalazine. A Review of its Use in the Management of Rheumatoid Arthritis. Drugs. 2005;65(13):1825–49.
  • 26. Lim W, Wang Y, MacDonald J, Hanauer S. Aminosalicylates for treatment of active Crohn’s disease. Cochrane Database Syst Rev Plain Lang Summ [Internet]. 2016;(7):CD008870.
  • 27. Papich M. Leki w weterynarii. Małe i duże zwierzęta. Błażejewska E (red.). Wrocław: Elsevier Urban&Partner; 2011.
  • 28. Bielińska M, Nałęcz-Jawecki G. Zanieczyszczenie Środowiska przyrodniczego lekami. I: Ocena toksyczności trzech fluorochinolonów dla rzęsy drobnej Lemna minor. Biul Wydz Farm WUM. 2009;4:24–30.
  • 29. Szymonik A, Lach J. Zagrożenie środowiska wodnego obecnością środków farmaceutycznych. Inżynieria i Ochr Środowiska. 2012;15(3):249–63.
  • 30. Ziemiańska J, Papla P, Baran W, Adamek E, Sobczak A, Lipska I. Proces fotokatalityczny wybranych sulfonamidów w obecności TiO2, FeCl3 i TiO2/FeCl3. Proc ECOpole. 2013;7(1):427–34.
  • 31. Ziemiańska J, Adamek E, Sobczak A, Lipska I, Makowski A, Baran W. The study of photocatalyctic degradation of sulfonamides applied to municipal wastewater. Physicochem. Probl. Mineral. Processing 2010; 45:127-140.
  • 32. Adamek E, Baran W, Sobczak A. Effect of FeCl3 on the photocatalytic processes initiated by UVa and vis light in the presence of TiO2-P25. Appl. Catal. B-Environ. 2015;172:136-144.
  • 33. Adamek E, Baran W, Sobczak A. Photocatalytic degradation of veterinary antibiotics: Biodegradability and antimicrobial activity of intermediates. Process Saf. Environ. Protect. 2016;103(A):1-9.
  • 34. Muszyńska B, Rojowski J, Łazarz M, Kała K, Dobosz K, Opoka W. The accumulation and release of Cd and Pb from edible mushrooms and their biomass. Pol J Food Nutr Sci. 2018;27: 1-8.
  • 35. Dąbrowska M, Muszyńska B, Starek M, Żmudzki P, Opoka W. Degradation pathway of cephalosporin antibiotics by in vitro cultures of Lentinula edodes and Imleria badia. International Biodeter Biodeg. 2018;127:104–112.
  • 36. Lang E, Eller, Kleeberg R, Martens R, Zadrazil F. Interaction of white rot fungi and microorganisms leading to biodegradation of soil pollutants. Proceedings of the 5th International FZK/ TNo Conference on contaminated soil. 30th Oct- 5Nov 1995, Maustrient.1277-1278.
  • 37. Riva S. Laccases: blue enzymes for green chemistry. Trends Biotechnol. 2006;24: 219-226.
  • 38. Eldridge H.C, Milliken A, Farmer C, Hampton A, Wendland N, Coward L, Gregory DJ, Johnson CM. Efficient remediation of 17α-ethinylestradiol by Lentinula edodes (shiitake) laccase. Biocatal Agricult Biotech. 2017;10: 64–68.
Document Type
minireview
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-957798a4-4a09-456f-b22d-802eed9eda6e
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.